Autocrine pathway of angiopoietins-Tie2 system in AML cells: Association with phosphatidyl-inositol 3 kinase

Hematology Journal

Volumn 5, Issue 4, 2004, Pages 353-360

  Wakabayashi, Motohiro ^a   Miwa, Hiroshi ^a   Shikami, Masato ^a   Hiramatsu, Akihito ^a   Ikai, Toshiko ^a   Tajima, Emi ^a   Yamamoto, Hidesuke ^a   Miura, Kazuhisa ^a   Satoh, Atsushi ^a   Itoh, Masato ^a   Imamura, Akira ^a   Mihara, Hidetsugu ^a   Katoh, Yoshiro ^a   Nitta, Masakazu ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AML; Angiopoietins; Phosphatidyl inositol 3 kinase; Tie2

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; EXEMESTANE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RECEPTOR ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER THERAPY; CELL COUNT; CELL GROWTH; CELL STRAIN HL 60; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; RECEPTOR BINDING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOPOIETINS; BONE MARROW; CELL LINE, TUMOR; DNA PRIMERS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; RECEPTOR, TIE-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 4544373099     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200410     Document Type: Article

References (30)

1. Fennie C, Cheng J, Dowbenko D, Young P, Lasky LA. CD34+ endothelial cell lines derived from murine yolk sac induce the proliferation and differentiation of yolk sac CD34+ hematopoietic progenitors. Blood 1995; 86: 4454-4467.
2. Mukouyama Y, Hara T, Xu M, Tamura K, Donovan PJ, Kim H et al. In vitro expansion of murine multipotential hematopoietic progenitors from the embryonic aortagonad-mesonephros region. Immunity 1998; 8: 105-114.
3. Takakura N, Watanabe T, Suenobu S, Yamada Y, Noda T, Ito Y et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000; 102: 199-209.
4. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-313.
5. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
6. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
7. Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol 2001; 80: 695-705.
8. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
9. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
10. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann- Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434.
11. Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Burger H et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16: 1302-1310.
12. de Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296-304.
13. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717-3721.
14. Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923-1930.
15. de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hahlen K, Kamps WA. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002; 8: 2856-2861.
16. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L et al. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long- term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857-10862.
17. Watarai M, Miwa H, Shikami M, Sugamura K, Wakabayashi M, Satoh A et al. Expression of endothelial cell-associated molecules in AML cells. Leukemia 2002; 16: 112-119.
18. Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996; 87: 1692-1697.
19. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 1997; 11: 479-484.
20. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
21. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-980.
22. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H et al. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 1999; 274: 30896-30905.
23. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 2000; 86: 24-29.
24. Harfouche R, Gratton JP, Yancopoulos GD, Noseda M, Karsan A, Hussain SN. Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases. FAS- EB J 2003; 17: 1523-1525.
25. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-1169.
26. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
27. Currie MJ, Gunningham SP, Han C, Scott PA, Robinson BA, Harris AL et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res 2001; 7: 918-927.
28. Ziegler SF, Bird TA, Schneringer JA, Schooley KA, Baum PR. Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. Oncogene 1993; 8: 663-670.
29. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T. Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985; 82: 6133-6137.
30. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39-51.